Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
Innovative Immunotherapy Approach in Chimeric Antigen Receptor based therapy for acute leukemia using transplantation of genetically modified hematopoietic stem cells.
FY 2018-19
Summary
Acute lymphoblastic leukemia is the most common pediatric cancer and, despite an 80% remission rate, it remains the most lethal pediatric cancer. A promising new therapeutic tool for resistant leukemias uses engineered T cells to express a chimeric antigen receptor (CAR) that allows specific recognition and killing of cancer cells. Despite the efficacy of this treatment in chemotherapy-refractory patients, 50% of patients do not respond or relapse because CAR T-cells get exhausted and/or do not persist in the patient. Also, it is associated with a life-threatening side effect, called cytokine release syndrome, which results from the simultaneous activation of the injected CAR-T cells. Hence, there is a need for improving this technology. We thus propose an alternative strategy consisting of inserting the CAR gene into the patient’s own hematopoietic stem cells (instead of T cells) and re-engraft them to ensure a continuous and progressive replenishment of CAR-T cells. With this method, the anti-leukemic effect would be prolonged and relapses could be tackled from the very first day. However, modifying stem cell would generate CAR bearing cells that should not express it. Hence, to limit the expression of the CAR only to the effector cells, we have developed a genetic tool that controls the expression of the receptor on T cells exclusively. In this project, we will test the effectiveness and safety of our new approach. We will use sophisticated humanized mouse models that are engrafted with the patient’s immune system and leukemia cell. This improved therapy would: 1) increase efficacy; 2) reduce side-effects; and 3) eliminate graft-vs-host disease risks associated with classic bone-marrow transplant. This research project could result in a rapid translation to clinic.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406459
Name
Dasari Harika
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Innovative Immunotherapy Approach in Chimeric Antigen Receptor based therapy for acute leukemia using transplantation of genetically modified hematopoietic stem cells.
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Lymphoblastic Leukemia; Cancer Immunotherapy; Chimeric Antigen Receptor; Humanized Mice; Modified Stem Cells; Specific Promoter; T Cells
Abstract
Acute lymphoblastic leukemia is the most common pediatric cancer and, despite an 80% remission rate, it remains the most lethal pediatric cancer. A promising new therapeutic tool for resistant leukemias uses engineered T cells to express a chimeric antigen receptor (CAR) that allows specific recognition and killing of cancer cells. Despite the efficacy of this treatment in chemotherapy-refractory patients, 50% of patients do not respond or relapse because CAR T-cells get exhausted and/or do not persist in the patient. Also, it is associated with a life-threatening side effect, called cytokine release syndrome, which results from the simultaneous activation of the injected CAR-T cells. Hence, there is a need for improving this technology. We thus propose an alternative strategy consisting of inserting the CAR gene into the patient’s own hematopoietic stem cells (instead of T cells) and re-engraft them to ensure a continuous and progressive replenishment of CAR-T cells. With this method, the anti-leukemic effect would be prolonged and relapses could be tackled from the very first day. However, modifying stem cell would generate CAR bearing cells that should not express it. Hence, to limit the expression of the CAR only to the effector cells, we have developed a genetic tool that controls the expression of the receptor on T cells exclusively. In this project, we will test the effectiveness and safety of our new approach. We will use sophisticated humanized mouse models that are engrafted with the patient’s immune system and leukemia cell. This improved therapy would: 1) increase efficacy; 2) reduce side-effects; and 3) eliminate graft-vs-host disease risks associated with classic bone-marrow transplant. This research project could result in a rapid translation to clinic.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dasari, Harika
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~